{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248698","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.872649+00:00","generated_at":"2026-05-30T07:18:13.015627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M","bullets":["Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.","Net loss $20.6M ($0.29/sh) vs $34.9M ($0.50/sh) YoY; product gross margin 61% vs 58%.","Raised $31M via ATM in Oct 2024; cash $90.3M, expects to fund operations into 2027.","Appointed Georgia Erbez CFO and Alison Moore new CTO (former Allogene CTO).","Licensed genomics enzyme portfolio to Alphazyme/Maravai; eligible for sales-based royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248698","json":"https://secwatch.observer/filing/0001193125-24-248698.json","markdown":"https://secwatch.observer/filing/0001193125-24-248698.md","text":"https://secwatch.observer/filing/0001193125-24-248698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/0001193125-24-248698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/d896975d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:18:13.015627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}